Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HIV nuclear fallout

The high non-response rate in a Phase III trial of a once-daily tablet containing lamivudine and abacavir in combination with tenofovir illustrates the complicated nature of HIV drug development. While the results suggest that this particular regimen is suboptimal, it is difficult to draw any larger conclusions about the utility of regimens containing three nucleoside reverse transcriptase inhibitors (NRTIs).
In the open-label ESS30009 trial run by GlaxoSmithKline plc (GSK; LSE:GSK), 49% of patients did not respond after eight weeks of treatment with Viread tenofovir from Gilead Sciences Inc. plus abacavir

Read the full 893 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE